SB‐656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone‐induced airway inflammation in humans
- 11 July 2011
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (2), 282-293
- https://doi.org/10.1111/j.1365-2125.2011.03968.x
Abstract
Receptor antagonists that block the binding of chemokines such as CXCL8 (IL-8) are effective in animals models of neutrophil-mediated inflammation. It has been hypothesized that selective inhibition of neutrophil trafficking and activation may be a useful adjunct for the treatment of inflammatory airway diseases such as chronic obstructive pulmonary disease or cystic fibrosis. A CXCR1/2 receptor antagonist has shown activity in an ozone challenge model in humans. SB-656933, a selective CXCR2 antagonist, is safe and well-tolerated at single doses and is shown to inhibit agonist (CXCL1)-mediated expression of the CD11b on peripheral blood neutrophils as well as ozone-induced airway neutrophilia in healthy subjects. To determine the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects. Flow cytometric determination of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg). A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers. Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg. Maximum inhibition (70%) relative to placebo was observed following administration of SB-656933 400 mg (95% CI 60%, 77%). This was sustained up to a dose of 1100 mg. Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner. Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, respectively. There was a corresponding reduction in myeloperoxidase concentrations in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3). SB-656933 was safe and well-tolerated at all doses. SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range. These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.Keywords
This publication has 33 references indexed in Scilit:
- Evidence that cathelicidin peptide LL‐37 may act as a functional ligand for CXCR2 on human neutrophilsEuropean Journal of Immunology, 2009
- Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputumThorax, 2008
- Fluticasone Propionate Protects against Ozone-Induced Airway Inflammation and Modified Immune Cell Activation Markers in Healthy VolunteersEnvironmental Health Perspectives, 2008
- Neutrophilic Inflammation as a Major Determinant in the Progression of Cystic FibrosisDrug News & Perspectives, 2006
- Neutrophils in Innate ImmunitySeminars in Respiratory and Critical Care Medicine, 2004
- Interleukin-8 Receptor (CXCR2) AntagonistsPublished by S. Karger AG ,2001
- Airway inflammatory response to ozone in subjects with different asthma severityEuropean Respiratory Journal, 1999
- Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP‐105,696 in man following single oral administrationBritish Journal of Clinical Pharmacology, 1998
- Human Chemokines: An UpdateAnnual Review of Immunology, 1997
- The Respiratory Responses of Subjects With Allergic Rhinitis To Ozone Exposure and Their Relationship To Nonspecific Airway ReactivityToxicology and Industrial Health, 1987